FOXM1’s interaction in myeloma cells with NEK2 (NIMA-related kinase 2) and the CDK4/6-Rb-E2F axis [12, 13] is of interest from a therapeutic viewpoint because CDK inhibition may be effective in myeloma [12, 58–60]. This evidence concerns the gene NEK2 and plasma cell myeloma.